- Amdocs reported an adjusted earnings per share (EPS) of $1.70 for the fourth quarter.
- This EPS matched the analysts’ estimate of $1.70.
- Compared to last year, the EPS increased from $1.42 to $1.70.
- Revenue for the fourth quarter was $1.26 billion.
- Revenue saw a growth of 1.7% year over year.
- The revenue matched the analysts’ estimate of $1.26 billion.
- Analyst recommendations for Amdocs include 6 buys and 2 holds, with no sell ratings.
A look at Amdocs Ltd Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 3 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts using the Smartkarma Smart Scores have indicated a neutral to positive long-term outlook for Amdocs Ltd. With a balanced score of 3 across Value, Dividend, Growth, and Resilience, the company seems to be holding steady in various key aspects. Additionally, with a Momentum score of 4, Amdocs Ltd shows promising signs of ongoing growth and market traction.
Amdocs Limited, a company specializing in providing information system solutions to telecommunications giants globally, is positioned moderately well according to the Smartkarma Smart Scores. While not excelling in any particular area, the company’s overall outlook appears stable and potentially on an upward trajectory in terms of momentum, which could bode well for its future performance.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
